Payment overview · 2025
General Payments
$751.52
31 reported records · 11 companies
Healthcare provider profile · identity verified
Eric Scott Petersen, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MAQUOKETA, IA · NPI 1538149042
Verified facts
What the public records show
CMS Open Payments records show Eric Scott Petersen, D.O. received $751.52 in general payments during 2025 across 31 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $233.54 | 31.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $184.10 | 24.5% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.92 | 11.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.88 | 8.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.79 | 7.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.90 | 4.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.75 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.46 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.08 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.06 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $10.04 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $530.54 | 29 |
| Education | $220.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $111.46 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $72.64 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $72.64 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $72.64 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $68.91 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $66.02 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.79 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.79 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.76 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.76 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $12.56 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $10.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 205 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 678 | 70 |
| Furosemide | Furosemide | 648 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 609 | 97 |
| Trazodone Hcl | Trazodone Hcl | 595 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 117 |
| Potassium Chloride | Potassium Chloride | 502 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 493 | 63 |
| Risperidone | Risperidone | 479 | 20 |
| Sertraline Hcl | Sertraline Hcl | 467 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 429 | 44 |
| Lorazepam | Lorazepam | 422 | 40 |
| Famotidine | Famotidine | 419 | 37 |
| Lisinopril | Lisinopril | 366 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 69 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 330 | 14 |
| Gabapentin | Gabapentin | 313 | 75 |
| Quetiapine Fumarate | Quetiapine Fumarate | 296 | 15 |
| Omeprazole | Omeprazole | 283 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 265 | 38 |
| Prednisone | Prednisone | 250 | 148 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 236 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 58 |
| Azithromycin | Azithromycin | 230 | 180 |
| Memantine Hcl | Memantine Hcl | 222 | 13 |
| Olanzapine | Olanzapine | 221 | 12 |
| Metformin Hcl | Metformin Hcl | 214 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 206 | 37 |
| Eliquis | Apixaban | 205 | 27 |
| Tramadol Hcl | Tramadol Hcl | 201 | 51 |
| Metformin Hcl Er | Metformin Hcl | 195 | 25 |
| Donepezil Hcl | Donepezil Hcl | 193 | 17 |
| Warfarin Sodium | Warfarin Sodium | 193 | 32 |
| Losartan Potassium | Losartan Potassium | 188 | 49 |
| Buspirone Hcl | Buspirone Hcl | 167 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 163 | 18 |
| Spironolactone | Spironolactone | 163 | 37 |
| Alprazolam | Alprazolam | 160 | 18 |
| Divalproex Sodium | Divalproex Sodium | 155 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 154 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 37 |
| Clonazepam | Clonazepam | 143 | 19 |
| Alendronate Sodium | Alendronate Sodium | 140 | 21 |
| Meloxicam | Meloxicam | 138 | 57 |
| Atenolol | Atenolol | 133 | 27 |
| Levetiracetam | Levetiracetam | 129 | 11 |
| Jardiance | Empagliflozin | 128 | 24 |
| Simvastatin | Simvastatin | 128 | 40 |
| Allopurinol | Allopurinol | 123 | 26 |
| Mirtazapine | Mirtazapine | 122 | 19 |
| Baclofen | Baclofen | 115 | 30 |
| Farxiga | Dapagliflozin Propanediol | 114 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 38 |
| Ramipril | Ramipril | 109 | 19 |
| Cephalexin | Cephalexin | 108 | 91 |
| Digoxin | Digoxin | 108 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 103 | 86 |
| Montelukast Sodium | Montelukast Sodium | 102 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 43 |
| Pregabalin | Pregabalin | 99 | 15 |
| Terazosin Hcl | Terazosin Hcl | 95 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 19 |
| Bupropion Xl | Bupropion Hcl | 87 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 87 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | suppressed |
| Carvedilol | Carvedilol | 85 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 84 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | suppressed |
| Aripiprazole | Aripiprazole | 83 | suppressed |
| Fluconazole | Fluconazole | 83 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 81 | 70 |
| Ezetimibe | Ezetimibe | 80 | 13 |
| Jantoven | Warfarin Sodium | 80 | suppressed |
| Glimepiride | Glimepiride | 79 | 23 |
| Bumetanide | Bumetanide | 78 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 77 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 14 |
| Mounjaro | Tirzepatide | 70 | 11 |
| Myrbetriq | Mirabegron | 70 | suppressed |
| Haloperidol | Haloperidol | 67 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 27 |
| Diltiazem 24hr Er | Diltiazem Hcl | 65 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 21 |
| Celecoxib | Celecoxib | 63 | 20 |
| Sucralfate | Sucralfate | 61 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 60 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 57 | suppressed |
| Finasteride | Finasteride | 56 | 14 |
| Propranolol Hcl | Propranolol Hcl | 54 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 33 |
| Valacyclovir | Valacyclovir Hcl | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 48 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 48 | suppressed |
| Ondansetron Odt | Ondansetron | 48 | 26 |
| Rytary | Carbidopa/Levodopa | 48 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 48 | suppressed |
| Dexamethasone | Dexamethasone | 47 | 44 |
| Irbesartan | Irbesartan | 47 | 18 |
| Levofloxacin | Levofloxacin | 46 | 36 |
| Ozempic | Semaglutide | 46 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | suppressed |
| Nabumetone | Nabumetone | 41 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 12 |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Enalapril Maleate | Enalapril Maleate | 33 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 11 |
| Estradiol | Estradiol | 32 | suppressed |
| Carbamazepine Er | Carbamazepine | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | 12 |
| Lactulose | Lactulose | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 31 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 13 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 12 |
| Metolazone | Metolazone | 26 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 26 |
| Glipizide | Glipizide | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | 11 |
| Probenecid | Probenecid | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Topiramate | Topiramate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 19 |
| Acarbose | Acarbose | 19 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Phenytoin | Phenytoin | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Dexilant | Dexlansoprazole | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | 15 |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $751.52 · 31 records | Teva Pharmaceuticals USA, Inc. | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Repatha, Sunosi, UBRELVY, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error